Shots:

• The P-III (PSOARING 3) extension study evaluates tapinarof (qd) in adult patients with PsO. The results were presented at Winter Clinical Dermatology 2022
• The results demonstrated high rates of satisfaction across all evaluated parameters. Additionally, 78.5% (n=599) of patients who completed the survey showed that 81.7% considering more effective, 85.8% can manage psoriasis with tapinarof, 82.5% will continue to use tapinarof if available
• The US FDA has accepted an application for tapinarof to treat PsO in Aug 2021 & assigned a PDUFA date in Q2’22. Tapinarof is a steroid-free, cosmetically elegant topical cream & a therapeutic aryl hydrocarbon receptor modulating agent for PsO & AD

Ref: Businesswire | Image: